This issue comes out as breast cancer specialists from around the world gather in Vienna for the 15th biannual St Gallen International Breast Cancer Conference, to discuss what we’ve learnt over the past two years about [more]
Brain tumours are tough to treat for so many reasons. Progress depends almost entirely on the steadfast commitment of doctors working within international networks. Peter McIntyre talked to some of them, to hear about their [more]
Clonal evolution and the ‘survival of the nastiest’ remain the chief obstacles to curing cancer. But what if we could find a way to use the principles of evolution to beat evolving cancers cells at [more]
How is it possible to help patients decide on the best treatment option for them, when they are scared, and when there is such uncertainty? Elżbieta Senkus, a specialist in breast and prostate cancers, talks [more]
With increasing numbers of cancer drugs being approved on shorter trials that involve fewer patients, getting accurate reports of adverse events and side effects after approval is increasingly important. Maria Delaney reports on efforts to [more]
Stimulating development of more and better paediatric cancer drugs will be key to making progress, particularly in some of the hardest-to-treat childhood cancers. Gilles Vassal, past-President of the European Society for Paediatric Oncology, outlines emerging [more]
Bradford Hesse and colleagues explore insights gained from over a decade of data gathered by the US National Cancer Institute to monitor changes in the communication environment regarding cancer-related information. This is an abridged version [more]
Chemotherapy. That’s the word Jana Hermann doesn’t want to hear under any circumstances. She has breast cancer; she received the diagnosis four weeks ago. She underwent surgery to remove one of her breasts and five [more]
Anna Wagstaff looks at changes in the business, regulatory and science arenas that could open the way to delivering better cancer treatments, faster and cheaper. Of 91 new therapies approved for solid tumours between 2002 [more]